ImmunityBio, Inc. (IBRX) Balance Sheet

The balance sheet is deteriorating rapidly: equity swung from -$489.1M in 2024Q4 to -$1.0B in 2026Q2, a $511M decline in six quarters. This erosion is driven by cumulative losses exceeding $1.6B over the period, as reported in financial statements, and suggests that revenue growth has not yet offset the heavy R&D and SG&A investments. The trend implies that without a significant improvement in operating leverage, the company will continue to consume capital at an unsustainable pace.

The debt profile is volatile: total debt peaked at $1.1B in 2026Q1, then collapsed to $38.7M in 2026Q2, a 96% reduction. This dramatic swing likely reflects a debt-to-equity conversion or restructuring, possibly involving related-party transactions, as the company's history suggests. The absence of a D/E ratio in the data further complicates leverage assessment, but the rapid change indicates that debt management is a critical tool for survival, not a strategic choice. Investors should monitor the terms of any new financing, as the company's negative equity and high burn rate may force dilutive or high-cost capital raises.

The asset mix is evolving: net PP&E has decreased by 18.6% over the period, from $178.7M to $145.5M, which may indicate asset sales or impairments, despite the company's stated commitment to internal manufacturing. Goodwill fell from $16.6M to $11.8M, implying potential impairment charges. The increase in cash to $75.7M in 2026Q2, though down from $205.2M in 2026Q1, suggests a focus on liquidity. This trend may indicate that the company is prioritizing cash preservation over long-term asset investment, which could undermine its manufacturing moat if sustained.

Equity quality is poor: the company has never generated positive retained earnings, and the deficit has grown by $1.1B over the last six quarters. This is consistent with the income statement's negative profitability and suggests that all financing is debt or equity issuance, not internal generation. The lack of share repurchases or dividends, as noted in cash flow analysis, indicates that all capital is directed to operations. The negative equity position may limit future borrowing capacity and increase reliance on dilutive equity raises, which could further pressure existing shareholders.

The current ratio of 5.72 appears healthy, but it is misleading given the company's cash burn. With a quarterly operating loss of $61.7M (from income statement), the $75.7M cash balance provides less than two quarters of runway. The high current ratio likely reflects low current liabilities relative to current assets, but the composition of current assets may include inventory and receivables that are not immediately convertible to cash. This suggests that the company faces imminent financing needs, as highlighted in recent context flags, and may need to raise capital within the next two quarters to avoid liquidity constraints.